Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2017 07:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Provide Update on Phase 3 REGENERATE Trial of Obeticholic Acid for the Treatment of NASH Patients with Liver Fibrosis

NEW YORK, Feb. 10, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel...
January 04, 2017 16:05 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at Upcoming Investor Conference

NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
December 14, 2016 07:00 ET | Source: Intercept Pharmaceuticals, Inc.

European Commission Grants Intercept’s Ocaliva® (obeticholic acid) Marketing Authorization for the Treatment of Primary Biliary Cholangitis

NEW YORK, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel...
December 09, 2016 17:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at Upcoming Investor Conference

NEW YORK, Dec. 09, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
November 11, 2016 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Presents New Data at AASLD Examining the Effects of Ocaliva® (Obeticholic Acid) on Non-Invasive Assessments of Liver Fibrosis in Patients with PBC

NEW YORK, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel...
November 03, 2016 07:05 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update

Net Ocaliva® (obeticholic acid or OCA) 3Q sales of $4.7 million Positive opinion adopted by Committee of Medicinal Products in Human Use (CHMP) for Ocaliva in Primary Biliary Cholangitis (PBC) in...
November 01, 2016 07:05 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Announces Ocaliva® (Obeticholic Acid) Data in PBC to be Presented at the 2016 AASLD Annual Meeting

NEW YORK, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel...
October 28, 2016 16:05 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Report Third Quarter 2016 Financial Results on November 3

NEW YORK, Oct. 28, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
October 14, 2016 07:35 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva® (Obeticholic Acid) for the Treatment of Primary Biliary Cholangitis in the European Union

NEW YORK, Oct. 14, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel...
September 19, 2016 07:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Files New Drug Submission to Health Canada for Marketing Approval of Obeticholic Acid for the Treatment of Patients with Primary Biliary Cholangitis

New Drug Submission filed to Health Canada for obeticholic acid for PBCSubmission granted priority reviewIf approved, obeticholic acid would represent first new treatment option for PBC in 20...